Treatment of hepatitis C virus infection in patients of northern India

Journal of Gastroenterology and Hepatology (Australia)

Volumn 19, Issue 9, 2004, Pages 1058-1065

  Hazari, Sidhartha ^a   Panda, Subrat Kumar ^a   Gupta, Siddharth Datta ^a   Batra, Yogesh ^a   Singh, Rajbir ^a   Acharya, Subrat Kumar ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Chronic hepatitis; Disease characteristics; Genotype; Hepatitis C virus; Therapeutic response; Viral load

Indexed keywords

ALPHA2B INTERFERON; RIBAVIRIN;

ADULT; ARTICLE; BIOCHEMISTRY; BLOOD TRANSFUSION; CLINICAL CHEMISTRY; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG RESPONSE; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INDIA; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RELAPSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; VIROLOGY; VIRUS RESISTANCE; VIRUS TRANSMISSION;

EID: 4544244705     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2004.03405.x     Document Type: Article

References (37)

1. Kuo G, Choo QL, Alter HJ et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989; 244: 362-4.
2. Alter MJ, Margolis HS, Krawczynski K et al. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N. Engl. J. Med. 1992; 327: 1899-905.
3. Panigrahi AK, Panda SK, Dixit RK et al. Magnitude of hepatitis C virus infection in India: prevalence in healthy blood donors, acute and chronic liver diseases. J. Med. Virol. 1997; 51: 167-74.
4. Irshad M, Acharya SK, Joshi YK. Prevalence of hepatitis C virus antibodies in the general population and in selected groups of patients in Delhi. Indian J. Med. Res. 1995; 102: 162-4.
5. Arankalle VA, Chadha MS, Jha J, Amarapurkar DN, Banerjee K. Prevalence of anti HCV antibodies in western India. Indian J. Med. Res. 1995; 101: 91-3.
6. Chadha MS, Tungatkar SP, Arankalle VA. Insignificance prevalence of antibodies to hepatitis C in a rural area of western Maharastra. Indian J. Gastroenterol. 1999; 18: 22-3.
7. Chowdhury A, Santra A, Chaudhuri S et al. Hepatitis C virus infection in the general population: a community-based study in West Bengal, India. Hepatology 2003; 37: 802-9.
8. Acharya SK, Panda SK, Duphare H et al. Chronic hepatitis in a large Indian hospital. Natl Med. J. India 1993; 6: 202-6.
9. Panigrahi AK, Nanda SK, Dixit RK, Acharya SK, Zuckerman AJ, Panda SK. Diagnosis of hepatitis C virus-associated chronic liver disease in India: comparison of HCV antibody assay with a polymerase chain reaction for the 5′ non-coding region. J. Med. Virol. 1994; 44: 176-9.
10. Matsumoto A, Tanaka E, Suzuki T, Ogata H, Kiyosawa K. Viral and host factors that contribute to efficacy of interferon-alpha 2a therapy in patients with chronic hepatitis C. Dig. Dis. Sci. 1994; 39: 1273-80.
11. EASL. International Consensus Conference on hepatitis C. Paris, 26-27 February 1999. Consensus statement. J. Hepatol. 1999; 31 (Suppl. 1): 3-8.
12. Poynard T, Marcellin P, Lee SS et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352: 1426-32.
13. McHutchison JG, Poynard T. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. Semin. Liver Dis. 1999; 19 (Suppl. 1): 57-65.
14. Yoshioka K, Kakumu S, Wakita T et al. Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: relationship to genotypes of hepatitis C virus. Hepatology 1992; 16: 293-9.
15. Davis GL, Balart LA, Schiff ER et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N. Engl. J. Med. 1989; 321: 1501-6.
16. Desmet VJ. Histological classification of chronic hepatitis. Acta Gastroenterol. Belg. 1997; 60: 259-67.
17. Bylund DJ, McHutchison J. Autoimmune liver diseases. Clin. Lab. Med. 1997; 17: 483-97.
18. Hazari S, Acharya SK, Panda SK. Development and evaluation of a quantitative competitive reverse transcription polymerase chain reaction (RT-PCR) for hepatitis C virus RNA in serum using transcribed thio-RNA as internal control. J. Virol Methods 2004; 116: 45-54.
19. Panigrahi AK, Roca J, Acharya SK, Jameel S, Panda SK. Genotype determination of hepatitis C virus from northern India: identification of a new subtype. J. Med. Virol. 1996; 48: 191-8.
20. Raghuraman S, Shaji RV, Sridharan G et al. Distribution of the different genotypes of HCV among patients attending a tertiary care hospital in south India. J. Clin. Virol. 2003; 26: 61-9.
21. Amarapurkar D. Natural history of hepatitis C virus infection. J. Gastroenterol. Hepatol. 2000; 15: E105-10.
22. Valliammai T, Thyagarajan SP, Zuckerman AJ, Harrison TJ. Diversity of genotypes of hepatitis C virus in southern India. J. Gen. Virol. 1995; 76: 711-16.
23. Martinot-Peignoux M, Marcellin P, Pouteau M et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995; 22: 1050-6.
24. Alter MJ, Kruszon-Moran D, Nainan OV et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N. Engl. J. Med. 1999; 341: 556-62.
25. Sakugawa H, Nakasone H, Kinjo F et al. Clinical features of patients with chronic liver disease associated with hepatitis C virus genotype 1a/I in Okinawa, Japan. J. Gastroenterol. Hepatol. 1997; 12: 176-81.
26. Greene WK, Cheong MK, Ng V, Yap KW. Prevalence of hepatitis C virus sequence variants in South-East Asia. J. Gen. Virol. 1995; 76: 211-15.
27. Martinot-Peignoux M, Roudot-Thoraval F, Mendel I, et al. Hepatitis C virus genotypes in France: relationship with epidemiology, pathogenicity and response to interferon therapy. The GEMHEP. J. Viral Hepat. 1999; 6: 435-43.
28. Jenkins PJ, Cromie SL, Bowden DS, Finch CF, Dudley FJ. Chronic hepatitis C and interferon alfa therapy: predictors of long term response. Med. J. Aust. 1996; 164: 150-2.
29. Pereira LM, Spinelli V, Ximenes RA et al. Chronic hepatitis C infection: influence of the viral load, genotypes, and GBV-C/HGV coinfection on the severity of the disease in a Brazilian population. J. Med. Virol. 2002; 67: 27-32.
30. Weiland O, Braconier JH, Fryden A, Norkrans G, Reichard O, Uhnoo I. Influence of pre-treatment factors on outcome of interferon-alpha treatment of patients with chronic hepatitis C. Scand. J. Infect. Dis. 1999; 31: 115-18.
31. Martinot-Peignoux M, Boyer N, Pouteau M et al. Predictors of sustained response to alpha interferon therapy in chronic hepatitis C. J. Hepatol. 1998; 29: 214-23.
32. Berg T, Sarrazin C, Herrmann E et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 2003; 37: 600-9.
33. Weiland O. Interferon and ribavirin combination therapy: indications and schedules. Forum (Genova) 2000; 10: 22-8.
34. McHutchison JG, Gordon SC, Schiff ER et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N. Engl. J. Med. 1998; 339: 1485-92.
35. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
36. Civeira MP, Prieto J. Early predictors of response to treatment in patients with chronic hepatitis C. J. Hepatol. 1999; 31 (Suppl. 1): 237-43.
37. Cornberg M, Wedemeyer H, Manns MP. Treatment of chronic hepatitis C with PEGylated interferon and ribavirin. Curr. Gastroenterol Rep. 2002; 4: 23-30.